Evidence map›Paper›PMID 32875729›Full record

ArticleThoracic cancer2020

Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.

Xiaoguang Yang, Dongxue Zhao, Yanfeng Li, Yanyu Li, Wei Cui, Yuxin Li, Han Li, Xinyu Li, Dun Wang

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Unveiling the Molecular Landscape ofInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaoguang YangSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.ORCID 0000-0002-0021-6595
Dongxue ZhaoSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Yanfeng LiSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Yanyu LiSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Wei CuiDepartment of pharmacology, School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, China.
Yuxin LiDepartment of pharmacology, School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, China.
Han LiDepartment of pharmacology, School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, China.
Xinyu LiDepartment of pharmacology, School of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, China.
Dun WangSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh expression of monoamine oxidase A (MAOA) in non-small cell lung cancer (NSCLC) is related to epithelial-mesenchymal transition (EMT) and the development of clinicopathological features of NSCLC. Nevertheless, the role of MAOA in drug resistance still remains unclear. Hence, the aim of this article was to evaluate a previously synthesized MAOA inhibitor (G11) on inhibiting paclitaxel-resistant NSCLC metastasis and growth.

methodsFirst, MAOA expression level was evaluated in several NSCLC cell lines. An MTT assay was used to validate the inhibitory effect of G11 on NSCLC cells in vitro. Second, gene expression in G11-treated H460/PTX cells was analyzed by microarray gene expression. Third, transwell assay was performed to assess the invasion and metastasis of G11-treated A549/PTX and H460/PTX cells and western blot assay used to analyze vital protein expression level in G11-treated H460/PTX cells. Finally, the antimetastatic effect of G11 was tested in an NSCLC in vivo model.

resultsOur data revealed that G11 significantly inhibited the viability of paclitaxel (PTX)-resistant NSCLC cell lines (A549/PTX and H460/PTX). G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels. Additionally, G11 was found to hinder A549/PTX and H460/PTX cell migration and invasion. Furthermore, the in vivo study indicated that the coadministration of G11 and paclitaxel significantly suppressed tumor metastasis in H460/PTX lung metastasis models.

conclusionsThese findings indicated G11 showed a moderate inhibitory effect on paclitaxel-resistant NSCLC metastasis and growth, and support further investigation on MAOA potentially as a promising therapeutic target for paclitaxel-resistant NSCLC treatment. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Inhibition of MAOA might contribute to the suppression of metastasis and growth in PTX-resistant NSCLC cells. What this study adds This study explored the potential function of MAOA in drug-resistant NSCLC and might consider MAOA as a promising target for the treatment of drug-resistant NSCLC.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationHumansLung NeoplasmsMonoamine Oxidase InhibitorsNeoplasm MetastasisPaclitaxelAntineoplastic Agents, PhytogenicMonoamine Oxidase InhibitorsPaclitaxelDrug resistanceheptamethine carbocyanine dyemonoamine oxidase Anon-small cell lung cancer

Identifiers

PMID32875729
PMCPMC7529581
OpenAlexW3081874629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.